Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 08, 2018 16:01 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals Reports First Quarter 2018 Financial Results

HOUSTON, May 08, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
April 20, 2018 16:05 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals Announces Closing of Public Offering

HOUSTON, April 20, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for...
April 17, 2018 18:26 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals Announces Pricing of Public Offering of Common Stock

HOUSTON, April 17, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies...
April 16, 2018 16:42 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals Announces Proposed Public Offering of Common Stock

HOUSTON, April 16, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies...
April 11, 2018 16:17 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Announces Clinical Hold Lifted on U.S. Studies of BPX-501

HOUSTON, April 11, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
March 13, 2018 16:01 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals Provides Operational Update and Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2017

Recruitment completed in European BP-004 registration trial of BPX-501 and rimiducid Positive BPX-501 interim results reported in AML and primary immunodeficiencies GoCAR-T...
March 13, 2018 07:00 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Announces Interim Results Showing Low Rates of Cancer Recurrence in Pediatric AML Patients Treated with BPX-501

Company also reports encouraging disease-free survival and overall survival rates in pediatric patients with primary immunodeficiencies A pediatric registration trial is being planned HOUSTON, March...
March 06, 2018 07:00 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call and Webcast on March 13, 2018

HOUSTON, March 06, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
February 23, 2018 07:00 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Announces Update on Clinical Hold of U.S. BPX-501 Studies

HOUSTON, Feb. 23, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
February 21, 2018 07:00 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals Appoints Edmund P. Harrigan, M.D. to its Board of Directors

HOUSTON, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...